Healthcare / Medical Instruments & SuppliesSES
$0.93
+0.00 (+0.54%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $222.6M · quality 67.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
18.6x
↓EV/EBITDA
2.3x
↓ROE
14.1%
↑Gross Margin
30.0%
↓Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-7.5%
FCF CAGR
-3.2%
FCF margin
22.4%
FCF / Net income
1.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $995.3M · net income $207.8M · FCF $222.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $995.3M | $995.3M | $1.07B | $914.8M | $1.26B |
| Net Income | $207.8M | $207.8M | $286.9M | $220.4M | $314.4M |
| EBITDA | $336.0M | $336.0M | $423.6M | $339.8M | $479.9M |
| EPS | 0.14 | 0.14 | 0.19 | 0.15 | 0.21 |
| Gross Margin | 30.0% | 30.0% | 36.4% | 32.3% | 35.8% |
| Operating Margin | 24.5% | 24.5% | 30.8% | 27.1% | 31.1% |
| Net Margin | 20.9% | 20.9% | 26.7% | 24.1% | 25.0% |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.00 | 0.00 | — |
| Cash Flow | |||||
| Free Cash Flow | $222.6M | $222.6M | $227.2M | $197.4M | $245.0M |
| Returns | |||||
| ROE | 14.1% | 14.1% | 18.2% | 13.1% | 17.0% |
| Valuation | |||||
| P/E | 18.60 | 18.60 | 5.58 | 4.77 | 2.83 |
| EV/EBITDA | 2.25 | 2.25 | 2.13 | 0.56 | -0.31 |
| P/B | 0.93 | 0.93 | 1.02 | 0.63 | 0.48 |
| Growth & Yield | |||||
| Revenue Growth | -7.2% | -7.2% | 17.3% | -27.4% | — |
| EPS Growth | -27.6% | -27.6% | 30.2% | -29.9% | — |
| Dividend Yield | 7.0% | 7.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-16.2%
EPS terminal req.
$0.08
Spread vs growth
-11.4%
5Y implied EPS CAGR
-6.6%
EPS terminal req.
$0.10
Spread vs growth
-21.0%
10Y implied EPS CAGR
1.4%
EPS terminal req.
$0.16
Spread vs growth
-29.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+43.7%
Start / end P/E
3.5x → 6.6x
EPS bridge
0.19 → 0.14
Residual
-24.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.